Breast Cancer Research and Treatment

Determinants of tissue estradiol levels and biologic responsiveness in breast tumors

Wei Yue, Steven J. Santner, Shigeru Masamura, Ji-Ping Wang, Laurence M. Demers, Christopher Hamilton, Richard J. Santen

Biochemical control of breast aromatase

A. Singh, A. Purohit, N.G. Coldham, M.W. Ghilchik, M.J. Reed

Molecular analysis of aberrant expression of aromatase in breast cancer tissues

Nobuhiro Harada, Shin-ichiro Honda

Intratumoral aromatase model: The effects of letrozole (CGS 20267)

Angela Brodie, Qing Lu, Wei Yue, Jiping Wang, Yang Liu

Clinical importance of intratumoral aromatase

W.R. Miller, P. Mullen, J. Telford, J.M. Dixon

Discussion

Theoretical considerations for the ideal aromatase inhibitor

M. Dowsett

Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer

Per E. Lønning

Pharmacological and clinical profile of anastrozole

Per E. Lønning, Jürgen Geisler, Mitch Dowsett

Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor

Paul E. Goss

Fadrozole and letrozole in advanced breast cancer: Clinical and biochemical effects

Ian E. Smith, Alison Norton

Discussion

Immunolocalization of aromatase in human breast disorders using different antibodies

Hironobu Sasano, Hiroshi Murakami

Aromatase expression in the human breast

Angela Brodie, Brian Long, Qing Lu

Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts

R.J. Santen, J. Martel, M. Hoagland, F. Naftolin, L. Roa, N. Harada, L. Hafer, R. Zaino, R. Pauley, S. Santner

Comparison of biochemical aromatase activity with aromatase immunhistochemistry in human breast carcinomas

K.C. Shenton, M. Dowsett, Q. Lu, A. Brodie, H. Sasano, N.P.M. Sacks, M.G. Rowlands

Dr. Richard Santen's editorial changes to discussion following the Friday morning 11 July 1997 session 'Immunochemical approaches to assessing intratumoral aromatase'